Kyle Swanson

I'm a PhD student in Computer Science at Stanford University. My research focuses on machine learning applied to biomedicine and drug discovery.

[Sylvain Gariel @SylvainGariel]

https://t.co/Jkqf8gdfz6

[Sylvain Gariel @SylvainGariel]

Oral GLP-1s make 1 thing clear: patients want pills. But orals, small molecules especially, are still brutally hard to develop. A close look at why the oral small molecule problem persists, and how the AI wave may finally solve it.
With Isomorphic's $2.1B raise and multiple programs in Phase 3, the first AI-enabled oral drug could be approved within the next few years.
“The future has already arrived. It’s just not evenly distributed yet.”

https://t.co/nUXQxi03OW

[Sylvain Gariel @SylvainGariel]

https://t.co/B31WSQ0vMi

[Sylvain Gariel @SylvainGariel]

https://t.co/S6xX2C0TuQ

[Sylvain Gariel @SylvainGariel]

Sutton's Bitter Lesson has a bitter footnote in drug discovery.

Two atoms turned xanomeline into Cobenfy ($14B Karuna acquisition). One residue separates sotorasib's modest PFS from daraxonrasib's near-doubling of OS in pancreatic cancer.

Pure scale won't get you there anytime soon. ↓

https://t.co/Q5qeKE9YCj

[Josh Gruenstein @joshgruenstein]

Excited to share @tutorintel's Data Factory 1, a 100 robot semi-humanoid research farm and the largest robot data factory in the United States.

Our first embodiment “Cassie” is deployed at industrial scale across the supply chain. We built DF1 to bootstrap fleet-scale learning for our "Sonny" industrial semi-humanoid embodiment, powered by our first end-to-end robot foundation model Ti0.

[Kyle Swanson @KyleWSwanson]

Thank you @alanchengsf, Maria Chiriac, @james_y_zou, and all of our other colleagues at Merck for a great project and a really unique opportunity to apply SyntheMol-RL to real-world drug discovery programs! 5/5

[Kyle Swanson @KyleWSwanson]

Following our publication of SyntheMol-RL last week, I'm excited to share the results and learnings from an extensive collaboration with @Merck applying SyntheMol-RL to two of their internal drug discovery pipelines. 1/5
https://t.co/b3p4Sd7E0r

[Kyle Swanson @KyleWSwanson]

We share our results and learnings on two internal programs at Merck: a human therapeutic program and an antibacterial program. We were excited to see promising preliminary results on both projects. We also discuss challenges and share takeaways for future work. 4/5

[James Zou @james_y_zou]

>700K people die every year due to S. aureus infection.

SyntheMol-RL created a new molecule that stops drug-resistant S. aureus MRSA—validated in mice studies.

AI accelerating drug discovery; published today!👇

Great collab w/ @ItsJonStokes' lab led by @KyleWSwanson Gary Liu

[Kyle Swanson @KyleWSwanson]

SyntheMol-RL is fully open source for everyone to use. Thank you Gary Liu, Denise Catacutan, @ItsJonStokes, @james_y_zou, and our collaborators for a fun project! 6/6 https://t.co/u8wKb9fx6y

[Kyle Swanson @KyleWSwanson]

SyntheMol-RL has now been published! SyntheMol-RL is a reinforcement learning model for synthesizable small molecule drug design. We used it to design antibiotic candidates for the bacteria S. aureus with hits validated in vitro and in vivo in mice. 1/6 https://t.co/SuCMHik2tB

[Kyle Swanson @KyleWSwanson]

We tested one particularly potent molecule, which we call synthecin, in a mouse skin infection model of methicillin-resistant S. aureus (MRSA) and found that it was safe and highly effective at treating the infection. 5/6

[Kexin Huang @KexinHuang5]

Today we’re launching Phylo, a research lab studying agentic biology, backed by a $13.5M seed round co-led by @a16z and @MenloVentures / Anthology Fund @AnthropicAI.

We’re also introducing a research preview of Biomni Lab, the first Integrated Biology Environment (IBE), where we’re imagining a new way biologists work.

Biomni Lab uses agents to orchestrate hundreds of biological databases, software tools, molecular AI models, expert workflows, and even external research services in one workspace, supporting research end-to-end from question to experiment to result.

Agents handle the mechanics, while you define the question, then review, steer, and decide. Scientists end up spending more time on science: asking questions, understanding mechanisms, and eliminating diseases.

Phylo (@phylo_bio) is a spin-out of @ProjectBiomni, where we will maintain the open-source community and push open-science research. I’m grateful to continue building with my co-founders @YuanhaoQ @jure @lecong and the dream founding team @serena2z @TianweiShe @huangzixin20151 @gm2123 @margaretwhua @malayhgandhi.

We’re also fortunate to be advised by leading scientists @zhangf, Carolyn Bertozzi, and @fabian_theis, and supported by an amazing group of investors including @JorgeCondeBio @zakdoric Matt Kraning @ZettaVentures @dreidco @conviction @saranormous @svangel @valkyrie_vc and others.

Biomni Lab is available for free today: https://t.co/zYcXEjvIbb
Learn more in our launch post: https://t.co/O09cnwYeNg

We are also hosting launch events - join us at
South San Francisco: https://t.co/4Xm9DFf4cY
Virtual: https://t.co/Wf7ksnWkRy

We’re also hiring! https://t.co/PABaLLwmRx